Rapid regression of bone marrow fibrosis after dose-reduced allogeneic stem cell transplantation in patients with primary myelofibrosis

Experimental Hematology

Volumn 35, Issue 11, 2007, Pages 1719-1722

  Kröger, Nicolaus ^a   Thiele, Jürgen ^c   Zander, Axel ^a   Schwerdtfeger, Rainer ^b   Kobbe, Guido ^c   Bornhäuser, Martin ^d   Bethge, Wolfgang ^e   Schubert, Jörg ^f   de Witte, Theo ^g   Kvasnicka, Hans Michael ^h  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b DEUTSCHE KLINIK FÜR DIAGNOSTIK   (Germany)

^c UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^d UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^e UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^f SAARLAND UNIVERSITY   (Germany)

^g RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^h UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; ENDOTHELIAL CELL GROWTH FACTOR; FLUDARABINE; FLUDARABINE PHOSPHATE; LEUKOCYTE ANTIGEN;

ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ALLOGRAFT; ARTICLE; BONE MARROW BIOPSY; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; FEMALE; HUMAN; MALE; MYELOFIBROSIS; MYELOID METAPLASIA; POLYCYTHEMIA VERA; PRIORITY JOURNAL; REMISSION; RISK FACTOR; THROMBOCYTHEMIA;

ADULT; BONE MARROW EXAMINATION; BUSULFAN; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; KINETICS; MALE; MIDDLE AGED; MYELOFIBROSIS; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; VIDARABINE;

EID: 35448930206     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2007.08.022     Document Type: Article

References (23)

1. Mesa R.A., Verstovsek S., Cervantes F., et al. Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT). Leuk Res 31 (2007) 737-740
2. Barosi G. Myelofibrosis with myeloid metaplasia: diagnostic definition and prognostic classification for clinical studies and treatment guidelines. J Clin Oncol 17 (1999) 2954-2970
3. Tefferi A. Myelofibrosis with myeloid metaplasia. N Engl J Med 342 (2000) 1255-1265
4. Wang J.C., Lang H.D., Lichter S., Weinstein M., and Benn P. Cytogenetic studies of bone marrow fibroblasts cultured from patients with myelofibrosis and myeloid metaplasia. Br J Haematol 80 (1992) 184-188
5. Le Bousse-Kerdiles M.C., and Martyre M.C. Dual implication of fibrogenic cytokines in the pathogenesis of fibrosis and myeloproliferation in myeloid metaplasia with myelofibrosis. Ann Hematol 78 (1999) 437-444
6. Martyre M.C. Critical review of pathogenetic mechanisms in myelofibrosis with myeloid metaplasia. Curr Hematol Rep 2 (2003) 257-263
7. Dupriez B., Morel P., Demory J.L., et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood 88 (1996) 1013-1018
8. Kvasnicka H.M., Thiele J., Werden C., Zankovich R., Diehl V., and Fischer R. Prognostic factors in idiopathic (primary) osteomyelofibrosis. Cancer 80 (1997) 708-719
9. Okamura T., Kinukawa N., Niho Y., and Mizoguchi H. Primary chronic myelofibrosis: clinical and prognostic evaluation in 336 Japanese patients. Int J Hematol 73 (2001) 194-198
10. Strasser-Weippl K., Steurer M., Kees M., et al. Age and hemoglobin level emerge as most important clinical prognostic parameters in patients with osteomyelofibrosis: introduction of a simplified prognostic score. Leuk Lymphoma 47 (2006) 441-450
11. Rondelli D., Barosi G., Bacigalupo A., et al. Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia. Blood 105 (2005) 4115-4119
12. Kröger N., Zabelina T., Schieder H., et al. Pilot study of reduced-intensity conditioning followed by allogeneic stem cell transplantation from related and unrelated donors in patients with myelofibrosis. Br J Haematol 128 (2005) 690-697
13. Devine S.M., Hoffman R., Verma A., et al. Allogeneic blood cell transplantation following reduced-intensity is effective therapy for older patients with myelofibrosis with myeloid metaplasia. Blood 99 (2002) 2255-2258
14. Guardiola P., Anderson J.E., Bandini G., et al. Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Societe Francaise de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center Collaborative Study. Blood 93 (1999) 2831-2838
15. Thiele J., Kvasnicka H.M., Dietrich H., et al. Dynamics of bone marrow changes in patients with chronic idiopathic myelofibrosis following allogeneic stem cell transplantation. Histol Histopathol 20 (2005) 879-889
16. Thiele J., Kvasnicka H.M., Facchetti F., Franco V., van der Walt J., and Orazi A. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica 90 (2005) 1128-1132
17. Wang J.C., Chang T.H., Goldberg A., Novetsky A.D., Lichter S., and Lipton J. Quantitative analysis of growth factor production in the mechanism of fibrosis in agnogenic myeloid metaplasia. Exp Hematol 34 (2006) 1617-1623
18. Katoh O., Kimura A., Itoh T., and Kuramoto A. Platelet derived growth factor messenger RNA is increased in bone marrow megakaryocytes in patients with myeloproliferative disorders. Am J Hematol 35 (1990) 145-150
19. Bock O., Loch G., Schade U., von Wasielewski R., Schlue J., and Kreipe H. Aberrant expression of transforming growth factor beta-1 (TGF beta-1) per se does not discriminate fibrotic from non-fibrotic chronic myeloproliferative disorders. J Pathol 205 (2005) 548-557
20. Bock O., Neuse J., Hussein K., et al. Aberrant collagenase expression in chronic idiopathic myelofibrosis is related to the stage of disease but not to the JAK2 mutation status. Am J Pathol 169 (2006) 471-481
21. Deeg H.J., Gooley T.A., Flowers M.E., et al. Allogeneic hematopoietic stem cell transplantation for myelofibrosis. Blood 102 (2003) 3912-3918
22. Daly A., Song K., Nevill T., et al. Stem cell transplantation for myelofibrosis: a report from two Canadian centers. Bone Marrow Transplant 32 (2003) 35-40
23. Sale G.E., Deeg H.J., and Porter B.A. Regression of myelofibrosis and osteosclerosis following hematopoietic cell transplantation assessed by magnetic resonance imaging and histologic grading. Biol Blood Marrow Transplant 12 (2006) 1285-1294